Traders purchased shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading hours on Friday. $54.13 million flowed into the stock on the tick-up and $41.41 million flowed out of the stock on the tick-down, for a money net flow of $12.72 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 24th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($1.50) for the day and closed at $125.80

A number of research firms have weighed in on ALXN. Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 8th. Credit Suisse Group AG upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Saturday, July 9th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 30th. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 target price on the stock. Finally, Vetr upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $171.50 target price on the stock in a report on Wednesday, June 8th. Seven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $190.61.

The stock has a market cap of $28.18 billion and a PE ratio of 190.32. The firm’s 50-day moving average is $126.57 and its 200-day moving average is $141.81.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.13 by $0.02. The firm had revenue of $701 million for the quarter, compared to analyst estimates of $710.98 million. The business’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.28 earnings per share. Equities analysts predict that Alexion Pharmaceuticals Inc. will post $5.05 earnings per share for the current fiscal year.

In related news, EVP John B. Moriarty sold 918 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now directly owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Martin Mackay sold 4,097 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $139.20, for a total transaction of $570,302.40. Following the transaction, the executive vice president now directly owns 42,706 shares in the company, valued at $5,944,675.20. The disclosure for this sale can be found here.

A number of institutional investors have modified their holdings of ALXN. LS Investment Advisors LLC raised its position in shares of Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 89 shares during the last quarter. Sawtooth Asset Management Inc. raised its position in shares of Alexion Pharmaceuticals by 15,072.9% in the fourth quarter. Sawtooth Asset Management Inc. now owns 7,283 shares of the biopharmaceutical company’s stock valued at $1,389,000 after buying an additional 7,235 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares during the last quarter. Liberty Mutual Group Asset Management Inc. raised its position in shares of Alexion Pharmaceuticals by 3.1% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,522 shares of the biopharmaceutical company’s stock valued at $2,579,000 after buying an additional 409 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Alexion Pharmaceuticals by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,722 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 192 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.